OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer - Tutt, A; Garber, JE; Kaufman, B (J Clin Oncol, 2021)
et al.